Tracers / [131I]I-131-Lym-1
[131I]I-131-Lym-1
Also written as I-131-Lym-1
- Radionuclide
- I-131 t½ 11549 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 0
What it is
- Compound class
- radiolabeled antibody (radioimmunoconjugate)
- Target / mechanism
- Lym-1 antibody target (HLA-DR-like B-cell surface antigen) PMID 9406709
- Clinical application
- Patients with B-cell non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) with splenomegaly PMID 9406709
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
No synthesis has been parsed for this agent yet.
Need this precursor?We can point you to suppliers for [131I]I-131-Lym-1, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 5 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage 26: this agent has NO own synthesis/characterisation data in the current corpus -- its only linked run(s) were unlinked (empty-quote recheck: appeared only as a control/comparator or in the wrong article).